Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.09.2023 | editorial

Head and neck cancer revisited

verfasst von: Assoc. Prof. PD Dr. Thorsten Füreder

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Auszug

Head and neck cancer (HNC) is a heterogenous disease involving multiple anatomical subsites such as the oral cavity, pharynx, and larynx. While incidence rates have been increasing during the last few decades, HNC remains the seventh most common cancer resulting in approximately 325,000 annual deaths globally [1]. Well-recognized risk factors for the development of HNC include alcohol consumption, smoking tobacco products, betel nut chewing, human papilloma virus (HPV), and Epstein–Barr virus (EBV) infections. …
Vorheriger Artikel American Society of Hematology meeting update
Nächster Artikel Long-term survival and follow-up care after cancer in Austria
Literatur
1.
Gormley M, Creaney G, Schache A, et al. Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors. Br Dent J. 2022;233(9):780–6.CrossRefPubMedPubMedCentral
2.
Lechner M, Liu J, Masterson L, et al. HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. Nat Rev Clin Oncol. 2022;19(5):306–27.CrossRefPubMedPubMedCentral
3.
Leemans CR, Tiwari R, Nauta JJ, et al. Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer. 1994;73(1):187–90.CrossRefPubMed
4.
Sturgis EM, Miller RH. Second primary malignancies in the head and neck cancer patient. Ann Otol Rhinol Laryngol. 1995;104(12):946–54.CrossRefPubMed
5.
Lee NY, Ferris RL, Psyrri A, et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2021;22(4):450–62.CrossRefPubMed
6.
Tao Y, Biau J, Sun XS, et al. Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial. Ann Oncol. 2023;34(1):101–10.CrossRefPubMed
7.
Machiels JP, Tao Y, Burtness B, et al. LBA5 primary results of the phase III KEYNOTE-412 study: pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC). Ann Oncol. 2022;33:S1399.CrossRef
8.
Resl C, Georg P, Döller C. New developments in radiation oncology for head and neck cancers. memo. 2023;16(3).
9.
Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–27.CrossRefPubMed
10.
11.
Yu H, Yin X, Mao Y, et al. The global burden of nasopharyngeal carcinoma from 2009 to 2019: an observational study based on the global burden of disease study 2019. Eur Arch Otorhinolaryngol. 2022;279(3):1519–33.CrossRefPubMed
12.
Metadaten
Titel
Head and neck cancer revisited
verfasst von
Assoc. Prof. PD Dr. Thorsten Füreder
Publikationsdatum
01.09.2023
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2023
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-023-00907-z

Weitere Artikel der Ausgabe 3/2023

Next generation drugs in urothelial cancer: adenoviruses in the treatment of BCG-unresponsive nonmuscle invasive bladder cancer

  • short review

American Society of Hematology meeting update

  • editorial

Long-term survival and follow-up care after cancer in Austria

  • editorial

New developments in radiation oncology for head and neck cancers

  • Open Access
  • short review

Current systemic treatment options and new developments in palliative first-line treatment of head and neck squamous cell carcinoma

  • Open Access
  • short review

FlASHback—personal highlights regarding myelodysplastic syndrome from the 2022 ASH meeting

  • Open Access
  • short review